Eyepoint Pharmaceuticals (EYPT) Competitors $10.36 -0.70 (-6.33%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$10.33 -0.03 (-0.25%) As of 07/11/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock EYPT vs. TXG, TRNS, ALNT, LAB, CTKB, AEHR, QSI, QTRX, SENS, and MASSShould you be buying Eyepoint Pharmaceuticals stock or one of its competitors? The main competitors of Eyepoint Pharmaceuticals include 10x Genomics (TXG), Transcat (TRNS), Allient (ALNT), Standard BioTools (LAB), Cytek Biosciences (CTKB), Aehr Test Systems (AEHR), Quantum-Si (QSI), Quanterix (QTRX), Senseonics (SENS), and 908 Devices (MASS). These companies are all part of the "measuring and control equipment" industry. Eyepoint Pharmaceuticals vs. Its Competitors 10x Genomics Transcat Allient Standard BioTools Cytek Biosciences Aehr Test Systems Quantum-Si Quanterix Senseonics 908 Devices 10x Genomics (NASDAQ:TXG) and Eyepoint Pharmaceuticals (NASDAQ:EYPT) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends, media sentiment and earnings. Does the media favor TXG or EYPT? In the previous week, Eyepoint Pharmaceuticals had 5 more articles in the media than 10x Genomics. MarketBeat recorded 8 mentions for Eyepoint Pharmaceuticals and 3 mentions for 10x Genomics. 10x Genomics' average media sentiment score of 0.88 beat Eyepoint Pharmaceuticals' score of 0.66 indicating that 10x Genomics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 10x Genomics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Eyepoint Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, TXG or EYPT? 10x Genomics has a beta of 2.03, suggesting that its stock price is 103% more volatile than the S&P 500. Comparatively, Eyepoint Pharmaceuticals has a beta of 1.67, suggesting that its stock price is 67% more volatile than the S&P 500. Is TXG or EYPT more profitable? 10x Genomics has a net margin of -25.14% compared to Eyepoint Pharmaceuticals' net margin of -261.91%. 10x Genomics' return on equity of -23.22% beat Eyepoint Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets 10x Genomics-25.14% -23.22% -18.02% Eyepoint Pharmaceuticals -261.91%-54.27%-41.75% Which has higher earnings and valuation, TXG or EYPT? Eyepoint Pharmaceuticals has lower revenue, but higher earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Eyepoint Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio10x Genomics$610.78M2.58-$182.63M-$1.30-9.85Eyepoint Pharmaceuticals$43.27M16.47-$130.87M-$2.41-4.30 Do insiders & institutionals believe in TXG or EYPT? 84.7% of 10x Genomics shares are owned by institutional investors. Comparatively, 99.4% of Eyepoint Pharmaceuticals shares are owned by institutional investors. 9.4% of 10x Genomics shares are owned by insiders. Comparatively, 4.5% of Eyepoint Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Do analysts prefer TXG or EYPT? 10x Genomics currently has a consensus target price of $14.13, indicating a potential upside of 10.35%. Eyepoint Pharmaceuticals has a consensus target price of $25.67, indicating a potential upside of 147.75%. Given Eyepoint Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Eyepoint Pharmaceuticals is more favorable than 10x Genomics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 10x Genomics 1 Sell rating(s) 5 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.46Eyepoint Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 3.00 Summary10x Genomics and Eyepoint Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks. Get Eyepoint Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for EYPT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EYPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EYPT vs. The Competition Export to ExcelMetricEyepoint PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$761.05M$2.97B$5.62B$9.09BDividend YieldN/A2.39%5.24%4.00%P/E Ratio-4.3020.7128.1320.27Price / Sales16.47288.27428.2698.57Price / CashN/A42.8637.4658.16Price / Book2.107.638.045.49Net Income-$130.87M-$55.05M$3.18B$250.45M7 Day Performance5.35%8.43%3.62%4.79%1 Month Performance16.93%5.42%4.06%7.68%1 Year Performance0.29%2.03%30.01%16.43% Eyepoint Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EYPTEyepoint Pharmaceuticals1.7826 of 5 stars$10.36-6.3%$25.67+147.7%+4.5%$761.05M$43.27M-4.30120TXG10x Genomics4.5132 of 5 stars$11.58-1.3%$14.96+29.2%-24.7%$1.44B$610.78M0.001,240TRNSTranscat2.9611 of 5 stars$85.96+1.3%$114.00+32.6%-30.6%$790.33M$278.42M55.101,245News CoverageAnalyst ForecastALNTAllient2.3149 of 5 stars$36.31+1.1%$31.00-14.6%+46.6%$608.09M$529.97M26.222,525Positive NewsLABStandard BioTools3.5988 of 5 stars$1.20+0.8%$2.50+108.3%-32.7%$451.99M$174.43M-3.43620Positive NewsCTKBCytek Biosciences3.1186 of 5 stars$3.40-4.2%$5.60+64.7%-44.3%$449.64M$200.45M0.00500AEHRAehr Test Systems3.4956 of 5 stars$12.93+3.3%$25.00+93.3%-6.6%$372.74M$66.22M16.5890News CoverageEarnings ReportUpcoming EarningsAnalyst RevisionQSIQuantum-Si1.9937 of 5 stars$1.96+0.5%$3.48+77.3%+60.2%$357.82M$3.06M0.00150Gap DownQTRXQuanterix2.4181 of 5 stars$6.65flat$15.60+134.6%-58.2%$332.20M$137.42M-5.12460News CoverageSENSSenseonics2.1089 of 5 stars$0.48-3.6%$1.55+225.4%+5.9%$311.67M$23.68M-3.6690News CoveragePositive NewsAnalyst ForecastAnalyst RevisionMASS908 Devices1.2248 of 5 stars$7.13+5.9%$5.33-25.2%+30.0%$241.35M$59.63M0.0060Positive News Related Companies and Tools Related Companies TXG Alternatives TRNS Alternatives ALNT Alternatives LAB Alternatives CTKB Alternatives AEHR Alternatives QSI Alternatives QTRX Alternatives SENS Alternatives MASS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EYPT) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eyepoint Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eyepoint Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
